Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

  1. suPAR Michigan M2C2 Heterogeneity Cohort Study

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Severe Respiratory Distress Syndrome; Acute Respiratory Distress Syndrome <br/><b>Interventions</b>: Diagnostic Test: suPARnostic® TurbiLatex Assay on Roche cobas c501 <br/><b>Sponsors</b>: ViroGates A/S; University of Michigan <br/><b>Completed</b>

  2. RESCCUE4 - Group CBT for Social Anxiety in Adolescents

    Wed, 11 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Social Anxiety Disorder <br/><b>Interventions</b>: Behavioral: Group Cognitive Behavioral Therapy; Behavioral: Psychoeducational Group Intervention <br/><b>Sponsors</b>: Bambino Gesù Hospital and Research Institute; European Union <br/><b>Completed</b>

  3. A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

    Wed, 11 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Influenza, Human+COVID-19 <br/><b>Interventions</b>: Biological: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine; Biological: Licensed Seasonal Influenza Vaccine; Biological: Licensed COVID-19 Vaccine <br/><b>Sponsors</b>: GlaxoSmithKline <br/><b>Not yet recruiting</b>

  4. CARE Study for Paramedics in Singapore

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Post Traumatic Stress Disorder; Depression; Anxiety Disorders and Symptoms; Burnout; Psychological Distress <br/><b>Interventions</b>: Behavioral: Oxford-Online; Behavioral: Mind-Online <br/><b>Sponsors</b>: Singapore General Hospital; Duke-NUS Graduate Medical School <br/><b>Completed</b>

  5. Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome?

    Fri, 06 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: ME/CFS; Long COVID; Post- COVID-19 Syndrome; POTS - Postural Orthostatic Tachycardia Syndrome; Fibromyalgia; Overtraining Syndrome; Post-Viral Fatigue Syndrome; Mast Cell Activation Syndrome <br/><b>Interventions</b>: Behavioral: Swimming; Behavioral: Cycling <br/><b>Sponsors</b>: Simon Fraser University <br/><b>Recruiting</b>

  6. Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Healthy Volunteers <br/><b>Interventions</b>: Drug: Benfo-oxythiamine <br/><b>Sponsors</b>: Benfovir AG <br/><b>Completed</b>

  7. COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)

    Wed, 04 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Testing Behaviors <br/><b>Interventions</b>: Behavioral: COVID-19 rapid test-to-treat; Behavioral: Standard COVID19 education control arm <br/><b>Sponsors</b>: University of Missouri, Kansas City; National Institute on Minority Health and Health Disparities (NIMHD) <br/><b>Active, not recruiting</b>

  8. A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

    Wed, 04 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID -19; COVID-19 (Prevention) <br/><b>Interventions</b>: Biological: MDX2301; Biological: Normal Saline; Biological: Normal Saline; Biological: MDX2301 <br/><b>Sponsors</b>: ModeX Therapeutics, An OPKO Health Company <br/><b>Recruiting</b>

  9. Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; Anxiety; Rheumatic Diseases <br/><b>Interventions</b>: Other: Current treatment (no intervention assigned) <br/><b>Sponsors</b>: Bursa City Hospital <br/><b>Completed</b>

  10. Long-Term Health Effects of Previous COVID-19 in Patients Undergoing Preoperative Anesthesia Evaluation

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Post-COVID Condition; Long COVID; Sequelae of COVID-19 <br/><b>Interventions</b>: Other: Post-COVID Clinical Assessment <br/><b>Sponsors</b>: Elazıg Fethi Sekin Sehir Hastanesi <br/><b>Recruiting</b>

  11. Neural Network-Based Prediction in Critical COVID-19 Patients

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Pandemic <br/><b>Interventions</b>: Other: Artificial Neural Network (ANN) Analysis <br/><b>Sponsors</b>: University of Gaziantep <br/><b>Completed</b>

  12. Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Drug: Keytruda <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Not yet recruiting</b>

  13. Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Persistent COVID Condition <br/><b>Interventions</b>: Other: BioICOPER Long COVID Cohort <br/><b>Sponsors</b>: Instituto de Investigación Biomédica de Salamanca; Carlos III Health Institute <br/><b>Recruiting</b>

  14. A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 <br/><b>Interventions</b>: Biological: mRNA-1273; Biological: mRNA-1283; Biological: Placebo <br/><b>Sponsors</b>: ModernaTX, Inc. <br/><b>Recruiting</b>

  15. A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Aluminum Hydroxide Suspension; Biological: Boost-2867; Biological: CpG 7909; Other: Sodium Chloride, 0.9% <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  16. Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: PepGNP-COVID19; Other: Sterile Water for Injection <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  17. Community-Led COVID-19 Testing Intervention to Address Mistrust

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; Trust <br/><b>Interventions</b>: Behavioral: Community-led discussion <br/><b>Sponsors</b>: Old Dominion University <br/><b>Completed</b>

  18. Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Respiratory Tract Infection; Smell Disorder; Influenza; Rhinosinusitis; COVID-19; Depression; Parosmia; Hyposomia; Normosomia; Anosmia <br/><b>Sponsors</b>: National Institute on Deafness and Other Communication Disorders (NIDCD) <br/><b>Not yet recruiting</b>

  19. Treatment Outcomes in PASC Patients With Neurocognitive Impairment

    Tue, 03 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Sponsors</b>: Ohio State University <br/><b>Completed</b>

  20. COVID-19 Reactogenicity

    Wed, 04 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Nuvaxovid (NVX-CoV2705); Drug: mNEXSPIKE mRNA-1283 <br/><b>Sponsors</b>: Marcel Curlin <br/><b>Active, not recruiting</b>

  21. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    Wed, 04 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  22. PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

    Tue, 03 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID; Post Acute Sequelae of COVID-19 <br/><b>Interventions</b>: Drug: 11C-PS13 <br/><b>Sponsors</b>: National Institute of Mental Health (NIMH) <br/><b>Recruiting</b>

  23. Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Mucormycosis; Hematologic Malignancies; COVID-19 <br/><b>Sponsors</b>: Institute of Hematology & Blood Diseases Hospital, China <br/><b>Completed</b>

  24. Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Influenza; SARS-CoV-2 (COVID-19) Infection; Immune Response of Host <br/><b>Interventions</b>: Procedure: Bronchoscopy <br/><b>Sponsors</b>: Washington University School of Medicine; National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  25. Dysbiosis & Long COVID

    Mon, 02 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: Subjects with and without Long COVID <br/><b>Sponsors</b>: University of Chicago <br/><b>Recruiting</b>

  26. Cohort Study of Intraoperative Lung Protective Ventilation Trends in a Large Canadian Health Authority

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Lung Protective Ventilation; Intraoperative Ventilation; COVID; COVID - 19; Non-cardiac Surgery <br/><b>Sponsors</b>: Perseus Missirlis; University of British Columbia <br/><b>Completed</b>

  27. Building Community Resilience Program

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Resilience, Psychological; Burnout, Psychological; Stress, Psychological <br/><b>Interventions</b>: Behavioral: Building Community Resilience Program (BCR) <br/><b>Sponsors</b>: Icahn School of Medicine at Mount Sinai <br/><b>Recruiting</b>

  28. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Wed, 11 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 SARS-CoV-2 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: placebo <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  29. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Coronavirus Disease (COVID-19) <br/><b>Interventions</b>: Drug: Molnupiravir; Drug: Placebo <br/><b>Sponsors</b>: Merck Sharp & Dohme LLC <br/><b>Recruiting</b>

  30. Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust - Study 1

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; Trust <br/><b>Interventions</b>: Behavioral: Community-led discussion <br/><b>Sponsors</b>: Old Dominion University <br/><b>Completed</b>

  31. Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID; Sars-CoV-2 Infection; Coronavirus Infections; COVID-19 <br/><b>Interventions</b>: Drug: Baricitinib; Other: Placebo <br/><b>Sponsors</b>: Wes Ely; National Institutes of Health (NIH); National Institute on Aging (NIA) <br/><b>Recruiting</b>

  32. COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

    Tue, 10 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID 19; Influenza; Rheumatoid Arthritis (RA); Systemic Lupus Erthematosus; Inflammatory Bowel Disease; Solid Organ Transplant Recipients; Immunocompromised Host; People Living With HIV <br/><b>Interventions</b>: Biological: Inactivated influenza vaccine (IIV) at baseline; Biological: COVID-19 Vaccines at a 3-month interval; Biological: Inactivated influenza vaccine at Month 1; Biological: COVID-19 Vaccines at a 6-month interval <br/><b>Sponsors</b>: McGill University Health Centre/Research Institute of the McGill University Health Centre; Centre hospitalier de l'Université de Montréal (CHUM) <br/><b>Recruiting</b>

  33. A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

    Tue, 10 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 <br/><b>Interventions</b>: Biological: mRNA-1273 Variant-containing Formulation <br/><b>Sponsors</b>: ModernaTX, Inc. <br/><b>Recruiting</b>

  34. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: PASC Post Acute Sequelae of COVID-19 <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Recruiting</b>

  35. Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID; Pain <br/><b>Interventions</b>: Procedure: Acupuncture <br/><b>Sponsors</b>: University of Washington; National Center for Complementary and Integrative Health (NCCIH) <br/><b>Completed</b>

  36. Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

    Fri, 06 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Drug: Tonabersat; Drug: Placebo <br/><b>Sponsors</b>: Inflammx Therapeutics Inc <br/><b>Completed</b>

  37. Dime La VerDAD: Verify, Debunk, and Disseminate

    Mon, 02 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Influenza; COVID-19; Communication Research; Health Behavior; Respiratory Viral Infection <br/><b>Interventions</b>: Behavioral: Science Communication Curriculum Cohort 1; Behavioral: Science communication curriculum Cohort 2; Behavioral: Science communication curriculum Cohort 3; Behavioral: Science communication curriculum Cohort 4 <br/><b>Sponsors</b>: University of Chicago; University of Iowa; University of Michigan; Rush University Medical Center; Bedford Research Corporation, Inc.; Tanoma Consulting; National Institute on Minority Health and Health Disparities (NIMHD) <br/><b>Recruiting</b>

  38. RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

    Fri, 06 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Long COVID; Long Covid19; Long Covid-19 <br/><b>Interventions</b>: Behavioral: Personalized Cardiopulmonary Rehabilitation; Other: Education <br/><b>Sponsors</b>: Duke University; National Heart, Lung, and Blood Institute (NHLBI) <br/><b>Active, not recruiting</b>

  39. Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: SARS CoV 2 Infection <br/><b>Interventions</b>: Biological: BIMERVAX <br/><b>Sponsors</b>: Hipra Scientific, S.L.U; Veristat, Inc.; VHIR; Asphalion <br/><b>Completed</b>

  40. Edge AI-deployed DIGItal Twins for PREDICTing Disease Progression and Need for Early Intervention in Infectious and Cardiovascular Diseases Beyond COVID-19 - Investigation of Biomarkers in Dermal Interstitial Fluid

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Heart Failure <br/><b>Interventions</b>: Device: Use of the PELSA System for dISF extraction <br/><b>Sponsors</b>: Charite University, Berlin, Germany <br/><b>Completed</b>

  41. Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV2 Infection <br/><b>Interventions</b>: Biological: PHH-1V81; Biological: Comirnaty Omicron XBB1.5 <br/><b>Sponsors</b>: Hipra Scientific, S.L.U <br/><b>Completed</b>

  42. Psychosomatic, Physical Activity or Both for Post-covid19 Syndrom

    Fri, 06 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Post-COVID-19 Syndrome <br/><b>Interventions</b>: Behavioral: Exercise Therapy; Behavioral: Psychotherapy <br/><b>Sponsors</b>: Hannover Medical School; Health Insurance Audi BKK; occupational health service Volkswagen AG; Helmholtz Centre for Infection Research <br/><b>Active, not recruiting</b>

  43. Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy

    Fri, 06 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Post COVID-19 Condition (PCC) <br/><b>Interventions</b>: Other: Digital intervention (DiLCoS); Other: Data collection <br/><b>Sponsors</b>: University Hospital, Basel, Switzerland; State Secretariat for Education Research and Innovation, Switzerland; European Union's Horizon Europe research and innovation programme <br/><b>Active, not recruiting</b>

  44. Characterization of the Immunometabolic Signature in Long COVID-19.

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Biological: Blood sample (at inclusion and 6 months later); Other: Patient questionnaires (at inclusion and 6 months later) <br/><b>Sponsors</b>: University Hospital, Angers <br/><b>Completed</b>

  45. COVID-19 ANtibody Responses in Cystic Fibrosis: CAR-CF

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; Cystic Fibrosis <br/><b>Sponsors</b>: Hospital Universitari Vall d'Hebron Research Institute; Queen's University, Belfast; European Cystic Fibrosis Society - Clinical Trials Network; Cystic Fibrosis Foundation; Hospital Vall d'Hebron <br/><b>Completed</b>

  46. A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Chronic Lymphocytic Leukemia; COVID-19 Infection <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Biological: mRNA COVID-19 Vaccine; Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 <br/><b>Sponsors</b>: City of Hope Medical Center; National Cancer Institute (NCI) <br/><b>Recruiting</b>

  47. Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Post COVID-19 Condition <br/><b>Interventions</b>: Behavioral: Personalized multidisciplinary day-hospital intervention <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin <br/><b>Completed</b>

  48. A Study of Modified mRNA Vaccines in Healthy Adults

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2; Seasonal Influenza; Respiratory Syncytial Virus; Cytomegalovirus <br/><b>Interventions</b>: Biological: mRNA-1273; Biological: mRNA-1010; Biological: mRNA-1345; Biological: FLUAD®; Biological: mRNA-1647 <br/><b>Sponsors</b>: ModernaTX, Inc. <br/><b>Completed</b>

  49. Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Systemic Inflammation; Neuroinflammation; Microvascular Thrombosis <br/><b>Interventions</b>: Drug: IV normal saline; Drug: IV immunoglobulin <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Enrolling by invitation</b>

  50. Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.

    Tue, 03 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: Tozinameran - Standard Dose; Biological: Tozinameran - Fractional Dose <br/><b>Sponsors</b>: Murdoch Childrens Research Institute; Coalition for Epidemic Preparedness Innovations; The Peter Doherty Institute for Infection and Immunity <br/><b>Completed</b>

  51. T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 Infection <br/><b>Interventions</b>: Biological: Coronavirus-specific T cell (CST) <br/><b>Sponsors</b>: Children's National Research Institute <br/><b>Recruiting</b>

  52. Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

    Wed, 11 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS-CoV-2 Acute Respiratory Disease <br/><b>Interventions</b>: Biological: COVID-19 Vaccine HIPRA; Biological: Cominarty (Pfizer-BioNtech) <br/><b>Sponsors</b>: Hipra Scientific, S.L.U; Laboratorios Hipra, S.A. <br/><b>Completed</b>

  53. Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia; Pneumonia, Viral; Respiratory Infection; COVID-19 Acute Respiratory Distress Syndrome <br/><b>Interventions</b>: Drug: AV-001 Injection; Drug: AV-001 Placebo Injection <br/><b>Sponsors</b>: Vasomune Therapeutics, Inc. <br/><b>Recruiting</b>

  54. COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

    Tue, 03 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Breast Cancer, NOS <br/><b>Interventions</b>: Other: Questionnaire <br/><b>Sponsors</b>: Eastern Cooperative Oncology Group <br/><b>Terminated</b>

  55. Autoimmune Intervention Mastery Course Study

    Wed, 11 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Multiple Sclerosis; Clinically Isolated Syndrome; Fibromyalgia; Post Acute Sequelae of COVID-19; Cancer in Remission With Persisting Fatigue <br/><b>Interventions</b>: Behavioral: Immediate Autoimmune Intervention Mastery Course (AIM); Behavioral: Immediate Question and Answer sessions. (AIM Q and A sessions); Behavioral: Delayed Autoimmune Intervention Mastery Course (delayed AIM course); Behavioral: Delayed AIM Question and Answer sessions <br/><b>Sponsors</b>: Terry L. Wahls <br/><b>Recruiting</b>

  56. Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Cancer Institute (NCI) <br/><b>Completed</b>

  57. Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

    Fri, 06 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Anosmia; Asymptomatic COVID-19; COVID-19 Respiratory Infection; Influenza; Healthy; PASC Post Acute Sequelae of COVID 19 <br/><b>Interventions</b>: Device: AROMHA Longitudinal Smell Test <br/><b>Sponsors</b>: Massachusetts General Hospital; National Institute on Deafness and Other Communication Disorders (NIDCD) <br/><b>Active, not recruiting</b>

  58. Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Severe/Moderate Coronavirus; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Old Age <br/><b>Interventions</b>: Biological: Blood samples <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; Gustave Roussy, Cancer Campus, Grand Paris; URC-CIC Paris Descartes Necker Cochin <br/><b>Withdrawn</b>

  59. Total-Body Parametric 18F-FDG PET of COVID-19

    Tue, 10 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Device: uEXPLORER/mCT <br/><b>Sponsors</b>: University of California, Davis <br/><b>Completed</b>

  60. Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV)

    Wed, 04 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19; SARS-CoV-2 <br/><b>Interventions</b>: Diagnostic Test: Blood count; Diagnostic Test: Blood collection; Diagnostic Test: Nasopharyngeal swab; Diagnostic Test: Saliva samples; Diagnostic Test: Faeces samples; Genetic: Genetic blood collection; Other: Data collection <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; Fonds IMMUNOV; URC-CIC Paris Descartes Necker Cochin <br/><b>Completed</b>

  61. WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Covid19; Cardiovascular Complication; Behavioral Changes <br/><b>Sponsors</b>: Tulane University; Biostrap <br/><b>Completed</b>

  62. COVID-19 Burnout Study

    Wed, 04 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Stress <br/><b>Interventions</b>: Behavioral: Mindfulness Based Intervention <br/><b>Sponsors</b>: University Health Network, Toronto <br/><b>Active, not recruiting</b>

  63. Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Adult Patients With Lesions on Fingers or Toes <br/><b>Interventions</b>: Other: Blood sampling; Other: Skin biopsy <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; Institut Cochin; URC-CIC Paris Descartes Necker Cochin <br/><b>Withdrawn</b>

  64. VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 Disease <br/><b>Sponsors</b>: University of Alabama at Birmingham <br/><b>Completed</b>

  65. COVID-19 on Placental Gene Expression and Pathology

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS-CoV-2 Infection <br/><b>Interventions</b>: Diagnostic Test: Positive for SARS-CoV-2 infection <br/><b>Sponsors</b>: Prisma Health-Upstate <br/><b>Completed</b>

  66. Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 Infection; COVID-19 <br/><b>Interventions</b>: Diagnostic Test: Nasopharyngeal swab; Diagnostic Test: Saliva sample; Diagnostic Test: axillary sweat sample; Other: Data collection <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin <br/><b>Completed</b>

  67. Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

    Thu, 05 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Post-Coronavirus Disease 19 <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Recruiting</b>

  68. Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

    Tue, 10 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; COVID-19-Associated Acute Respiratory Distress Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed <br/><b>Interventions</b>: Other: Best Practice; Biological: Mesenchymal Stem Cell <br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI) <br/><b>Recruiting</b>

  69. Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study

    Wed, 04 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Diagnostic Test: Brainstem Responses Assessment Sedation Score (BRASS); Diagnostic Test: Electroencephalogram with EKG lead <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin <br/><b>Completed</b>

  70. I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Remdesivir; Drug: Imatinib Mesylate; Drug: Dexamethasone; Drug: Cenicriviroc; Drug: Icatibant; Drug: Apremilast; Biological: dornase alfa; Drug: Celecoxib; Drug: Famotidine; Biological: IC14; Drug: Aviptadil; Biological: narsoplimab; Drug: Cyproheptadine; Drug: Cyclosporine <br/><b>Sponsors</b>: QuantumLeap Healthcare Collaborative; University of California, San Francisco; University of Pennsylvania; Emory University; University of Alabama at Birmingham; University of Colorado, Denver; University of Southern California; Yale University; Wake Forest University Health Sciences; Sanford Health; Long Beach Memorial Medical Center; Georgetown University; University of California, Davis; Hoag Memorial Hospital Presbyterian; Main Line Health; DHR Health Institute for Research and Development; University of California, Irvine; Corewell Health; Kaiser Permanente; University of Michigan; West Virginia University; University of Miami; University Hospitals Cleveland Medical Center; Virtua Health; M.D. Anderson Cancer Center <br/><b>Active, not recruiting</b>

  71. Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

    Mon, 02 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Aprepitant injectable emulsion; Drug: Saline Placebo <br/><b>Sponsors</b>: Heron Therapeutics <br/><b>Terminated</b>

  72. A Longitudinal Study of COVID-19 Sequelae and Immunity

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  73. Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19

    Fri, 06 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Environmental Health Sciences (NIEHS) <br/><b>Completed</b>

  74. NCI COVID-19 in Cancer Patients, NCCAPS Study

    Thu, 12 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration <br/><b>Sponsors</b>: National Cancer Institute (NCI) <br/><b>Active, not recruiting</b>

  75. Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)

    Tue, 03 Mar 2026 05:00:00 -0000

    <b>Conditions</b>: Upper Respiratory Tract Infections; Virus; COVID; Virus Shedding; Virus Diseases <br/><b>Interventions</b>: Other: NaCl Solution <br/><b>Sponsors</b>: University of Edinburgh <br/><b>Terminated</b>

  76. PET/CT Imaging in COVID-19 Patients

    Tue, 10 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS-CoV-2 Infection <br/><b>Interventions</b>: Drug: 18F-αvβ6-BP <br/><b>Sponsors</b>: University of California, Davis <br/><b>Completed</b>

  77. Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Remdesivir <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin <br/><b>Completed</b>

  78. Positron Emission Tomography (PET) Imaging of Thrombosis

    Fri, 27 Feb 2026 05:00:00 -0000

    <b>Conditions</b>: Atrial Fibrillation; COVID-19; Cancer; Thrombosis <br/><b>Interventions</b>: Drug: [64Cu]FBP8; Device: PET/MR; Procedure: Blood Collection; Procedure: Electrocardiogram <br/><b>Sponsors</b>: Massachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) <br/><b>Recruiting</b>

  79. Viral Infections in Healthy and Immunocompromised Hosts

    Mon, 09 Mar 2026 04:00:00 -0000

    <b>Conditions</b>: Anogenital Herpes; COVID-19; Herpes Labialis <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>